[1] |
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence⁃based changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017,67(6):472⁃492. doi: 10.3322/caac.21409.
|
[2] |
Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high⁃risk melanoma: a systematic review and meta⁃analysis[J]. J Natl Cancer Inst,2010,102(7):493⁃501. doi: 10.1093/jnci/djq009.
|
[3] |
Hodi FS, O′Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010,363(8):711⁃723. doi: 10.1056/NEJMoa100 3466.
|
[4] |
Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE⁃006): post⁃hoc 5⁃year results from an open⁃label, multicentre, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2019,20(9):1239⁃1251. doi: 10.1016/S1470⁃2045(19)30388⁃2.
|
[5] |
Eggermont A, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma[J]. N Engl J Med, 2018,378(19):1789⁃1801. doi: 10.1056/NEJMoa1802357.
|
[6] |
Larkin J, Chiarion⁃Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23⁃34. doi: 10.1056/NEJMoa1504030.
|
[7] |
Robert C, Grob JJ, Stroyakovskiy D, et al. Five⁃year outcomes with dabrafenib plus trametinib in metastatic melanoma[J]. N Engl J Med, 2019,381(7):626⁃636. doi: 10.1056/NEJMoa1904 059.
|
[8] |
Erkes DA, Cai W, Sanchez IM, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis[J]. Cancer Discov, 2020,10(2):254⁃269. doi: 10.1158/ 2159⁃8290.CD⁃19⁃0672.
|
[9] |
Schilling B, Martens A, Geukes Foppen MH, et al. First⁃line therapy⁃stratified survival in BRAF⁃mutant melanoma: a retrospective multicenter analysis[J]. Cancer Immunol Immunother, 2019,68(5):765⁃772. doi: 10.1007/s00262⁃019⁃02311⁃1.
|
[10] |
Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma[J]. J Clin Oncol, 2006,24(26):4340⁃4346. doi: 10.1200/JCO.2006.06.2984.
|
[11] |
Guo J, Carvajal RD, Dummer R, et al. Efficacy and safety of nilotinib in patients with KIT⁃mutated metastatic or inoperable melanoma: final results from the global, single⁃arm, phase II TEAM trial[J]. Ann Oncol, 2017,28(6):1380⁃1387. doi: 10. 1093/annonc/mdx079.
|
[12] |
Bai X, Kong Y, Chi Z,et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases[J]. Clin Cancer Res,2017,23(20):6120⁃6127. doi: 10.1158/1078⁃0432.CCR⁃17⁃0980.
|
[13] |
Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non⁃randomised, open⁃label phase 2 study[J]. Lancet Oncol, 2013,14(3):249⁃256. doi: 10.1016/S1470⁃2045(13)70024⁃X.
|
[14] |
Li J, Huang Q, Long X, et al. Mitochondrial elongation⁃mediated glucose metabolism reprogramming is essential for tumour cell survival during energy stress[J]. Oncogene, 2017,36(34):4901⁃4912. doi: 10.1038/onc.2017.98.
|
[15] |
Li XX, Wang ZJ, Zheng Y, et al. Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation[J]. Mol Cell, 2018,69(3):480⁃492.e7. doi: 10.1016/j.molcel.2018.01.001.
|
[16] |
Zhou B, Zhang JY, Liu XS, et al. Tom20 senses iron⁃activated ROS signaling to promote melanoma cell pyroptosis[J]. Cell Res, 2018,28(12):1171⁃1185. doi: 10.1038/s41422⁃018⁃0090⁃y.
|
[17] |
Yang Y, Luo M, Zhang K, et al. Nedd4 ubiquitylates VDAC2/3 to suppress erastin⁃induced ferroptosis in melanoma[J]. Nat Commun, 2020,11(1):433. doi: 10.1038/s41467⁃020⁃14324⁃x.
|
[18] |
Guo W, Wang H, Yang Y, et al. Down⁃regulated miR⁃23a contributes to the metastasis of cutaneous melanoma by promoting autophagy[J]. Theranostics, 2017,7(8):2231⁃2249. doi: 10.7150/thno.18835.
|
[19] |
Ma M, Dai J, Tang H, et al. MicroRNA⁃23a⁃3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways[J]. Theranostics, 2019,9(4):945⁃960. doi: 10.7150/thno.30516.
|
[20] |
Wang L, Guo W, Ma J, et al. Aberrant SIRT6 expression contributes to melanoma growth: role of the autophagy paradox and IGF⁃AKT signaling[J]. Autophagy, 2018,14(3):518⁃533. doi: 10.1080/15548627.2017.1384886.
|
[21] |
Guo W, Ma J, Yang Y, et al. ATP⁃citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition[J]. Clin Cancer Res, 2020,26(11):2725⁃2739. doi: 10.1158/1078⁃0432.CCR⁃19⁃1359.
|
[22] |
Manzano JL, Layos L, Bugés C, et al. Resistant mechanisms to BRAF inhibitors in melanoma[J]. Ann Transl Med, 2016,4(12):237. doi: 10.21037/atm.2016.06.07.
|
[23] |
Han S, Ren Y, He W, et al. ERK⁃mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma[J]. Nat Commun, 2018,9(1):28. doi: 10.1038/ s41467⁃017⁃02354⁃x.
|
[24] |
Kong Y, Sheng X, Wu X, et al. Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy[J]. Clin Cancer Res, 2017,23(22):6946⁃6957. doi: 10.1158/1078⁃0432.CCR⁃17⁃0070.
|
[25] |
Kong Y, Si L, Li Y, et al. Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K⁃AKT⁃mTOR pathway inhibitors[J]. Clin Cancer Res, 2016,22(4):1018⁃1027. doi: 10.1158/1078⁃0432.CCR⁃15⁃1110.
|
[26] |
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018,359(6382):1350⁃1355. doi: 10.1126/ science.aar4060.
|
[27] |
Meng X, Liu X, Guo X, et al. FBXO38 mediates PD⁃1 ubiquitination and regulates anti⁃tumour immunity of T cells[J]. Nature, 2018,564(7734):130⁃135. doi: 10.1038/s41586⁃018⁃0756⁃0.
|
[28] |
Ma X, Bi E, Huang C, et al. Cholesterol negatively regulates IL⁃9⁃producing CD8+ T cell differentiation and antitumor activity[J]. J Exp Med, 2018,215(6):1555⁃1569. doi: 10.1084/jem.20171576.
|
[29] |
Liu H, Kuang X, Zhang Y, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3⁃PD⁃L1 axis[J]. Cancer Cell, 2020,37(3):324⁃339.e8. doi: 10.1016/j.ccell. 2020.02.006.
|
[30] |
Huang L, Li Y, Du Y, et al. Mild photothermal therapy potentiates anti⁃PD⁃L1 treatment for immunologically cold tumors via an all⁃in⁃one and all⁃in⁃control strategy[J]. Nat Commun, 2019,10(1):4871. doi: 10.1038/s41467⁃019⁃12771⁃9.
|
[31] |
Xu YP, Lv L, Liu Y, et al. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy[J]. J Clin Invest, 2019,129(10):4316⁃4331. doi: 10.1172/JCI129317.
|
[32] |
Yu J, Yan J, Guo Q, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD⁃1 blockade in Chinese patients with non⁃cutaneous melanoma[J]. Clin Cancer Res, 2019,25(21):6511⁃6523. doi: 10.1158/1078⁃0432.CCR⁃19⁃0475.
|
[33] |
Sheng X, Yan X, Chi Z, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death⁃1, in patients with metastatic mucosal melanoma: an open⁃label phase IB trial[J]. J Clin Oncol, 2019,37(32):2987⁃2999. doi: 10.1200/JCO.19.00210.
|
[34] |
Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti⁃tumor immunity[J]. Nat Immunol, 2018,19(7):723⁃732. doi: 10.1038/s41590⁃018⁃0132⁃0.
|
[35] |
Yang M, Chen S, Du J, et al. NK cell development requires Tsc1⁃dependent negative regulation of IL⁃15⁃triggered mTORC1 activation[J]. Nat Commun, 2016,7:12730. doi: 10.1038/ncomms 12730.
|
[36] |
Yu X, Lao Y, Teng XL, et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation[J]. Nat Commun, 2018,9(1):3157. doi: 10.1038/s41467⁃018⁃05676⁃6.
|
[37] |
Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second⁃line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE⁃151)[J]. Transl Oncol, 2019,12(6):828⁃835. doi: 10.1016/j.tranon.2019.02.007.
|
[38] |
Liu Y, Ma J, Yang Y, et al. Impact of interferon⁃alpha1b (IFN⁃α1b) on antitumor immune response: an interpretation of the promising therapeutic effect of IFN⁃alpha1b on melanoma[J]. Med Sci Monit, 2020,26:e922790. doi: 10.12659/MSM.922790.
|